Decrelip

• Antilipemic Agents
• Fribic Acid Derivatives
• ATC:C10AB04

• Apo-Gemfibrozil
• Bolutol
• Cholespid
• Decrelip
• Fibratol
• Fibrocit
• Gemfibril
• Gemfibromax
• Gemlipid
• Gen-Fibro
• Genlip
• Gevilon
• Hipolixan
• Jezil
• Lipozid
• Lipur
• Lopid
• Novo-Gemfibrozil
• Nu-Gemfibrozil

• No information avaliable

C₁₅H₂₂O₃

http://www.rxlist.com/cgi/generic/gemfib.htm

Decrelip FDA

P. L. CREGER, U.S. Pat. 3,674,836 (1972)

250.333 g/mol

61-63 ^oC

10 mg/mL (in base)

Solid

4.242

Tablets; Capsules

For treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately).

Well absorbed from gastrointestinal tract (within 1-2 hours).

Oral, mouse: LD₅₀ = 3162 mg/kg. Symptoms of overdose include abdominal cramps, diarrhea, joint and muscle pain, nausea, and vomiting.

Gemfibrozil is used to lower high triglyceride and cholesterol levels. Notify your physician if you are pregnant or nursing. Gemfibrozil should be taken 30 minutes before the morning and evening meals. This medication may cause dizziness or blurred vision; use caution while driving or operating hazardous machinery. Gemfibrozil may cause an increase in blood sugar. If you have diabetes mellitus, carefully monitor blood sugar levels. Notify your physician if you develop severe stomach pain, muscle pain or weakness, or unexplained fever.

Humans and other mammals